AETHLON MEDICAL, INC. (NASDAQ:AEMD) Files An 8-K Other EventsITEM 8.01 Other Events
On October 10, 2017, we announced that Nasdaq has formally notified us that we have demonstrated compliance with all applicable requirements for the continued listing of its common stock on The Nasdaq Capital Market, including the$2.5 millionstockholders' equity requirement. As previously disclosed, the Nasdaq Hearings Panel required us to evidence compliance with the stockholders' equity requirement byOctober 31, 2017. As a result of the foregoing, the Nasdaq compliance matter has been closed.
As of October 11, 2017, we have 15,073,455 shares of our common stock issued and outstanding.
About AETHLON MEDICAL, INC. (NASDAQ:AEMD)
Aethlon Medical, Inc. is a medical device company focused on creating devices for cancer, infectious disease and other life-threatening conditions. The Company operates through two segments: Aethlon, which represents its therapeutic business activities, and ESI, which represents its diagnostic business activities. The Company’s lead product is the Aethlon Hemopurifier, which is a device that selectively targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression. The Aethlon Hemopurifier sheds glycoproteins to treat infectious viral pathogens. In oncology indications, the Hemopurifier targets the removal of circulating exosomes, which are released to promote cancer progression and to seed the spread of metastasis. Through its subsidiary, Exosome Sciences, Inc. (Exosome), the Company is also developing exosome-based product candidates to diagnose and monitor neurological disorders and cancer.